Thursday 16 October, 2025
Objectives: Almost thirty years after the discovery of HIV-1, the AIDS epidemic is still not controlled. While the search for…
Read morePoster: Infection
A Mathematical Modelling Framework to Assess the Impact of Nevirapine-based Prophylaxis on vertical HIV Transmission
Thursday 16 October, 2025
Objectives: Single dose nevirapine (NVP) prophylaxis, administered to HIV-positive mothers before birth and to their newborns shortly after birth, is…
Read morePopulation Pharmacokinetics of Isoniazid in Children with Pulmonary Tuberculosis
Thursday 16 October, 2025
Background and Objectives: There is limited isoniazid pharmacokinetic information in children, and daily doses (4-6 mg/kg) derived from adult doses…
Read morePharmacokinetic/pharmacodynamic modeling and simulation for concentration-dependent bactericidal activity of a bicyclolide, modithromycin
Thursday 16 October, 2025
Objectives: The aim of this study was to develop a pharmacokinetic/pharmacodynamic (PK/PD) model of a bicyclolide, modithromycin, to explain its…
Read moreMiltefosine treatment failure in visceral leishmaniasis in Nepal is associated with low drug exposure
Thursday 16 October, 2025
Objectives: Recent reports indicated high miltefosine treatment failure rates for the neglected tropical disease visceral leishmaniasis (VL) on the Indian…
Read moreComparison of elimination and absorption pharmacokinetics of linezolid in cystic fibrosis patients by three nonlinear models
Thursday 16 October, 2025
Objectives: Linezolid, an oxazolidinone antibiotic used for the treatment of serious Gram-positive infections in cystic fibrosis patients (CFP), displays nonlinear…
Read moreExternal validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1 infected patients
Thursday 16 October, 2025
Objectives: Atazanavir increases bilirubin levels in patients in a concentration dependent manner. Due to less costly and readily available assays,…
Read moreBilirubin – a biomarker of atazanavir exposure in HIV/AIDS patients
Thursday 16 October, 2025
Objectives: The protease inhibitor (PI) atazanavir is currently recommended for the first line treatment of HIV-1 infected patients. Although elevated…
Read morePopulation pharmacokinetics and pharmacodynamics of lumefantrine in pregnant women with uncomplicated P. falciparum malaria.
Thursday 16 October, 2025
Objectives: Artemether-lumefantrine is the most widely used ACT in the world, but its efficacy in the treatment of malaria in…
Read morePopulation pharmacokinetics of lumefantrine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda
Thursday 16 October, 2025
Background: Pregnancy alters the pharmacokinetic properties of many antimalarial compounds which might result in lower drug exposure and increased risk…
Read more